Lung cancer screening: a literature review

Pier Luigi  Piovano; Federica Grosso; Gianmauro Numico; Antonio Maconi; Biagio Polla

doi:10.4081/wpph.2019.9211

Objectives: Critical analysis of Literature on Lung Cancer Screening, synthesis and balance between scientific evidence and real world applicability. Methodology: selection of the most relevant clinical trials on the topic. Results: the most representative and positive studies (NLST, NELSON and MILD) have been examined and discussed, pointing out their limits and unsolved issues. Conclusion: despite clear statistically positive and encouraging results, many concerns still remain about routine implementation in the real world, mainly on the costs, the need for expert and trained dedicated radiologists and technicians, the theorical advantage of shifting resources to smoking cessation programs, the possible next integration of new biological and genetic diagnostic tools.

AIOM/AIRTUM, I numeri del cancro in Italia, Ed. Intermedia, 2018. https://www.aiom.it/wp-content/uploads/2018/10/2018_NumeriCancro-operatori.pdf

Black WC, Gareen IF, Soneji SS, Sicks JD, Keeler EB, Aberle DR, Naeim A, Church TR, Silvestri GA, Gorelick J, Gatsonis C; National Lung Screening Trial Research Team. “Cost-effectiveness of CT screening in the National Lung Screening Trial”. NEJM Nov 6;371(19):1793-802, 2014. DOI: https://doi.org/10.1056/NEJMoa1312547

De Koning HJ, WCLC 2018, Abs. PL02.05

Doria-Rose VP, Szabo E. “Screening and prevention of lung cancer”. In: Kernstine KH, Reckamp KL, eds. Lung cancer: a multidisciplinary approach to diagnosis and management. New York: Demos Medical Publishing, 2010:53-72.

Gaëlle Coureau, L. Rachid Salmi, Cécile Etard, Hélène Sancho-Garnier, Catherine Sauvaget, Simone Mathoulin-Pélissier, “Low-dose computed tomography screening for lung cancer in populations highly exposed to tobacco: A systematic methodological appraisal of published randomised controlled trials”, European Journal of Cancer 61, 146-156, 2016. DOI: https://doi.org/10.1016/j.ejca.2016.04.006

Hasan N, Kumar R, Kavuru MS. “Lung cancer screening beyond low-dose computed tomography: the role of novel biomarkers”. Lung 2014;192:639–48. DOI: https://doi.org/10.1007/s00408-014-9636-z

Horeweg N, Scholten ET, de Jong PA, van der Aalst CM, Weenink C, Lammers JW, Nackaerts K, Vliegenthart R, ten Haaf K, Yousaf-Khan UA, Huevelmans MA, Thunnissen E, Oudkerk M, Mali W, de Koning HJ, “Detection of Lung Cancer through low-dose CT screening (NELSON): a prespeciefied analysis of screening test performance and interval cancers” Lancet Oncol Nov; 15(12): 1342-50, 2014. DOI: https://doi.org/10.1016/S1470-2045(14)70387-0

IASLC, World Conference on Lung Cancer, 2018

Langevin SM, Kratzke RA, Kelsey KT. “Epigenetics of lung cancer. Translational research”. J Lab Clin Med 2015;165:74–90.

Naidich DP, Marshall CH, Gribbin C, Arams RS, McCauley DI. “Low-dose CT of the lungs: preliminary observations”. Radiology;175:729-31, 1990.

Matthijs Oudkerk, Anand Devaraj, Rozemarijn Vliegenthart, Thomas Henzler, Helmut Prosch, Claus P Heussel, Gorka Bastarrika, Nicola Sverzellati, Mario Mascalchi, Stefan Delorme, David R Baldwin, Matthew E Callister, Nikolaus Becker, Marjolein A Heuvelmans, Witold Rzyman, Maurizio V Infante, Ugo Pastorino, Jesper HPedersen, Eugenio Paci, Stephen W Duffy, Harry de Koning, John K Fiel “European position statement on lung cancer screening”, Lancet Oncol; 18: e754-66, 2017. DOI: https://doi.org/10.1016/S1470-2045(17)30861-6

Paci E, “The narrow path to organized LDCT lung cancer screening programs in Europe”, J Thorac Dis; 10 (7): 4556-4564, 2018. DOI: https://doi.org/10.21037/jtd.2018.07.08

Pastorino U, Silva M, Sestini S, Sabia F, Boeri M, Cantarutti A, Sverzellati N, Sozzi G, Corrao G, Marchianò A, “Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy”, Annals of Oncology 0: 1–8, 2019. DOI: https://doi.org/10.1093/annonc/mdz169

Richard Peto, Sarah Darby, Harz Deo, Paul Silcocks, Elise Whitley, Richard Doll, “Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case - control studies”, BMJ, vol 321, 5 Aug 2000. DOI: https://doi.org/10.1136/bmj.321.7257.323

Pinsky PF, Church TR, Izmirlian G, Kramer BS, “The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology”, Cancer, Nov 15;119(22):3976-83, 2013. DOI: https://doi.org/10.1002/cncr.28326

Rai A, Doria-Rose VP, Silvestri GA, Yabroff KR, “Evaluating Lung cancer Screening Uptake, Outcomes, and Costs in the United States: Challenges With Existing Data and Recommendations for Improvement”, J Natl Cancer Inst. Apr 1; 111(4): 342-349, 2019. DOI: https://doi.org/10.1093/jnci/djy228

Silvestri GA, Vachani A, Whitney D, et al. “A bronchial genomic classifier for the diagnostic evaluation of lung cancer”. N Engl J Med 2015;373:243–51. DOI: https://doi.org/10.1056/NEJMoa1504601

Surgeon General Report, US Dept. Health and Human Services, 2014.

The National Lung Screening Trial Research Team. “The National Lung Screening Trial: overview and study design”. Radiology 2011;258:243-53. DOI: https://doi.org/10.1148/radiol.10091808

The National Lung Screening Trial Research Team. “Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening”. NEJM, vol. 35 no. 5, 2011.

Yousaf-Khan U, van der Aalst C, de Jong PA, Huevelmans M, Scholten E, Lammers JW, van Ooijen P, Nackaerts K,Weenink C, Groen H, Vliegenthart R, Ten Haaf K, Oudkerk M, de Koning H, “Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval”, Thorax, Jan;72(1): 48-76, 2017. DOI: https://doi.org/10.1136/thoraxjnl-2016-208655

Piovano, P. L., Grosso, F., Numico, G., Maconi, A., & Polla, B. (2019). Lung cancer screening: a literature review. Working Paper of Public Health, 7(1). https://doi.org/10.4081/wpph.2019.9211